Abstracts tagged "Mortality"

Abstract Number: 1668 • ACR Convergence 2022
Rheumatic Toxicities of Immune Checkpoint Inhibitors Predict Favourable Tumour Responses in Patients with Advanced Melanoma
Alana Bruce¹, Alexander M Menzies², Georgina V Long², Brian Fernandes³ and Fredrick Joshua⁴, ¹Macquarie University, Balaclava, Victoria, Australia, ²Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia, ³Royal Prince Alfred Hospital, Sydney, Australia, ⁴Macquarie University, Integrated Specialist Medical Care, Sydney, Australia
Background/Purpose: To estimate the frequency of rheumatic toxicities of immune checkpoint inhibitors (ICI) presenting as de novo or exacerbations of pre-existing rheumatic disease in patients…
Abstract Number: 0721 • ACR Convergence 2022
Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex
Ashley Archer¹, Ruth Topless², Angelo Gaffo¹, Nicola Dalbeth³, Lisa Stamp⁴, Philip Robinson⁵ and Tony Merriman², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵School of Clinical Medicine, University of Queensland, Brisbane, Australia
Background/Purpose: There is increasing evidence that rheumatoid arthritis (RA) is a risk factor for death related to COVID-19, however data on the risk of death…
Abstract Number: 1757 • ACR Convergence 2022
The Independent Impact of Gout on Mortality and Risk of Coronary Heart Disease Among Women – a Prospective Cohort Analysis of Women over 34 Years
Chio Yokose¹, natalie mccormick¹, na lu², amit johi³, Gary Curhan⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Boston, MA, ³Regeneron, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: The disease burden of female gout has increased in recent years.1 However, there remains a paucity of data on female gout, despite it being…
Abstract Number: 0764 • ACR Convergence 2022
No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
Tawnie Braaten¹, Brian Sauer², Gary Kunkel³, Jessica Walsh³, Jorge Rojas⁴, Bryant England⁵, Joshua Baker⁶ and Grant Cannon⁷, ¹University of Utah Hospitals and Clinics and VA Salt Lake City Health Care System, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³University of Utah, Salt Lake City, UT, ⁴George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁷Salt Lake City VA, Salt Lake city
Background/Purpose: Immune checkpoint inhibitor (ICI) use for the treatment of multiple cancers continues to expand. Data on ICI treatment in autoimmune disease is limited as…
Abstract Number: 1845 • ACR Convergence 2022
Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study
Pamela Doti¹, Ana Luisa Cunha², Armin Quispe Cornejo³, Ángela Nieto González¹, Andre Matos¹, Pedro Guevara Hernández¹, Pedro Castro Rebollo¹ and Gerard Espinosa Garriga¹, ¹Hospital Clínic, Barcelona, Spain, ²Hospital Senhora da Oliveira, Guimarães, Porto, Portugal, ³Erasme Hospital, Brussels, Belgium
Background/Purpose: To describe the clinical characteristics of a 20-year cohort of patients with systemic autoimmune diseases (SAD) admitted to a medical intensive care unit (ICU)…
Abstract Number: 0828 • ACR Convergence 2022
Impact of Hospitalization on Clinical Outcomes in Patients with Connective Tissue Disease-associated Interstitial Lung Disease
Navneet Kaur¹, Xianhong Xie², Anna Korogodina³, Krystal L. Cleven⁴, Bibi Ayesha⁵ and Anand Kumthekar⁶, ¹Touro University Medical Group, Sacramento, CA, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Department of Medicine, Montefiore Medical Center-Wakefield/Albert Einstein College of Medicine, Bronx, NY, ⁴Division of Pulmonary Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Tarrytown, NY, ⁶Division of Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue disease (CTD). The aim of our study…
Abstract Number: 1871 • ACR Convergence 2022
Hospitalization Outcomes for Acute Myocardial Infraction and Acute Heart Failure in Patients with Idiopathic Inflammatory Myopathies (IIM) from 2016-2019 National Inpatient Sample (NIS)
Zi Ying Li¹, Siyi Huang², Kevin Xi³, Deepan Dalal⁴ and Anthony Reginato⁵, ¹Roger Williams Medical Center, Providence, RI, ²UCSF Fresno, Fresno, CA, ³Brown University, Providence, ⁴Brown University School of Medicine, Providence, RI, ⁵Brown University, Providence, RI
Background/Purpose: Cardiovascular disease was encountered in 15% of hospital admission from 2016-2017 for patients with idiopathic inflammatory myopathies (IIM) based on the National Inpatient Sample…
Abstract Number: 0592 • ACR Convergence 2021
Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality
Srikanta Banerjee¹ and Stephanie Falls², ¹Walden University, Leola, ²PA Department of Health, Leola
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease which predominantly affects joints with varying severity. While RA has been found to be…
Abstract Number: 1296 • ACR Convergence 2021
Mortality and Survival in Argentinian Lupus Patients: A Multicenter Study
Maria Constanza Bertolaccini¹, Yessika Soria Curi², Luciana Gonzalez Lucero³, Gabriela Vanesa Espasa², Ana Lucia Barbaglia², Hector Raul Sueldo², Maria Lilia Leguizamon², Susana Marcela Mazza², Mirta Santana², Liliana Maria Galindo², Rodrigo Aguila Maldonado⁴, Mercedes Garcia⁵, Dafne Capelusnik⁶, Ivana Romina Rojas Tessel⁷, Eugenia Picco⁷, Maria Elena Crespo Espindola⁷, Romina Calvo⁸, Susana Roverano⁹, Micaela Ana Cosatti⁹, Cecilia Nora Pisoni⁹, Paola Andrea Avila¹⁰, Marina Micelli¹¹, Maria Hu¹², Lucia Alascio¹³, Maria Cecilia Goizueta¹⁴ and Veronica Ines Bellomio², ¹Hospital Padilla, San Miguel de Tucumán, Argentina, ²Hospital Padilla, Tucuman, Argentina, ³Janssen Cilag Farmaceutica SA, Tucuman, Argentina, ⁴HIGA San Martin La Plata, La Plata, Argentina, ⁵Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Hospital Señor del Milagro, Salta, Argentina, ⁸Hospital José María Cullen, Santa Fe, Argentina, ⁹CEMIC, Buenos Aires, Argentina, ¹⁰Hospital Ramos Mejía, Buenos Aires, Argentina, ¹¹Hospital General de Agudos, Ramos Mejía - CF, Buenos Aires, Argentina, ¹²Hospital José Maria Penna, Buenos Aires, Argentina, ¹³Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ¹⁴Sanatorio 9 de Julio, Tucuman, Argentina
Background/Purpose: The mortality in lupus patients is 2–3 times higher than the general population. However, survival in these patients has improved significantly and it is…
Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Pedro Gaspar¹, Filipa Farinha², Zara Sayar³, Maria Efthymiou,⁴, Hannah Cohen³ and David Isenberg², ¹Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…
Abstract Number: 0667 • ACR Convergence 2021
Active Screening for Gout Permits Identifying a Larger Cardiovascular Population at High Mortality Risk
Silvia Ruiz-Simón¹, Irene Calabuig², Miguel Gómez-Garberí³ and MARIANO ANDRES⁴, ¹Universidad Miguel Hernández, Alicante, Spain, ²Hospital General Universitario de Alicante, Alicante, Spain, ³Hospital Universitario San Juan de Alicante, San Juan de Alicante, Spain, ⁴Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: We have recently noted by active screening that about a third of gout cases in the cardiovascular population is not registered in records (Calabuig,…
Abstract Number: 1302 • ACR Convergence 2021
Year-3 Observational Follow-up of Belimumab Safety (Mortality and Malignancies) in Patients with SLE Who Completed a Phase 4, 52-Week, Randomized, Double-Blind Placebo-Controlled Safety Study
Saira Sheikh¹, Cheng-Chung Wei², Dana Tegzova³, William Stohl⁴, Ricardo Acayaba de Toledo⁵, Tamara Mucenic⁶, Mauricio Abello Banfi⁷, Kathleen Maksimowicz-McKinnon⁸, Carlos Abud-Mendoza⁹, Sandra Navarra¹⁰, Mercedes Garcia¹¹, Ignacio Garcia-De La Torre¹², Regina Kurrasch¹³, Sofia Fernandes¹⁴, Julia Harris¹⁵, Saima Muzaffar¹⁴, Norma Lynn Fox¹³, Andrew Liu¹⁶, Holly Quasny¹⁷ and David Roth¹³, ¹University of North Carolina Thurston Arthritis Research Center, and Department of Medicine, Division of Rheumatology, Allergy and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ²Institute of Medicine, Chung Shan Medical University; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan (Republic of China), ³Institute of Rheumatology, Prague, Czech Republic, ⁴University of Southern California Keck School of Medicine, Los Angeles, CA, ⁵Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil, ⁶Hospital Moinhos de Vento, Porto Alegre, Brazil, ⁷Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁸Henry Ford Hospital, Wayne State University, Detroit, MI, ⁹Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatología y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ¹²Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, ¹³GlaxoSmithKline, Collegeville, PA, ¹⁴GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, ¹⁵GlaxoSmithKline, Uxbridge, United Kingdom, ¹⁶GlaxoSmithKline, Brentford, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC
Background/Purpose: Belimumab (BEL) is a recombinant IgG1λ monoclonal antibody that is approved for treatment of systemic lupus erythematosus (SLE). Although clinical studies of BEL have…
Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
Abstract Number: 0684 • ACR Convergence 2021
Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
Yoshiyuki Abe¹, Masahiro Kogami², Makio Kusaoi², Kurisu Tada³, Ken yamaji⁴ and Naoto Tamura³, ¹Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo University, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Juntendo University School of Medicine Internal Medicine and Rheumatology, Tokyo, Japan
Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…
Abstract Number: 1372 • ACR Convergence 2021
Outcomes and Risk Factors for Respiratory Failure in Patients with Scleroderma Associated with ILD
Soumyasri Kambhatla¹, Augustine Manadan² and Amy Trang², ¹Rush University, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Scleroderma is associated with underlying ILD. About 48% those with diffuse cutaneous SSc and 26% of those with limited cutaneous SSc were found to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.